Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) saw an uptick in trading volume on Thursday . 1,779,641 shares traded hands during mid-day trading, an increase of 244% from the previous session’s volume of 517,172 shares.The stock last traded at $3.5050 and had previously closed at $3.46.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Truist Financial assumed coverage on shares of Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price target on the stock. Finally, Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $16.56.
View Our Latest Analysis on Inventiva
Inventiva Trading Down 2.5%
Inventiva (NASDAQ:IVA – Get Free Report) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.01 million during the quarter. On average, equities analysts forecast that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current fiscal year.
Institutional Trading of Inventiva
Several institutional investors have recently bought and sold shares of IVA. Seven Fleet Capital Management LP acquired a new position in Inventiva in the first quarter valued at about $1,111,000. Virtu Financial LLC acquired a new stake in shares of Inventiva during the fourth quarter worth approximately $60,000. ADAR1 Capital Management LLC bought a new position in shares of Inventiva in the fourth quarter valued at approximately $12,601,000. XTX Topco Ltd bought a new position in shares of Inventiva in the fourth quarter valued at approximately $84,000. Finally, Yu Fan bought a new position in shares of Inventiva in the fourth quarter valued at approximately $6,975,000. Institutional investors and hedge funds own 19.06% of the company’s stock.
About Inventiva
Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.
Featured Stories
- Five stocks we like better than Inventiva
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
- MarketBeat Week in Review – 06/22 – 06/26
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
